Fredag 25 April | 14:22:22 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-04-23 N/A Årsstämma
2026-02-13 08:00 Bokslutskommuniké 2025
2025-11-06 08:00 Kvartalsrapport 2025-Q3
2025-08-22 08:00 Kvartalsrapport 2025-Q2
2025-05-14 08:00 Kvartalsrapport 2025-Q1
2025-04-25 N/A X-dag ordinarie utdelning CI 0.00 SEK
2025-04-24 - Årsstämma
2025-02-14 - Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-14 - Kvartalsrapport 2024-Q1
2024-04-26 - X-dag ordinarie utdelning CI 0.00 SEK
2024-04-25 - Årsstämma
2024-02-16 - Bokslutskommuniké 2023
2023-11-03 - Extra Bolagsstämma 2023
2023-11-03 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-10 - Kvartalsrapport 2023-Q1
2023-04-21 - X-dag ordinarie utdelning CI 0.00 SEK
2023-04-20 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-11-04 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-06 - Kvartalsrapport 2022-Q1
2022-04-22 - X-dag ordinarie utdelning CI 0.00 SEK
2022-04-21 - Årsstämma
2022-02-18 - Bokslutskommuniké 2021
2021-10-22 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-08-09 - Extra Bolagsstämma 2021
2021-05-07 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning CI 0.00 SEK
2021-04-22 - Årsstämma
2021-02-19 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-06 - Kvartalsrapport 2020-Q2
2020-05-07 - Kvartalsrapport 2020-Q1
2020-04-17 - X-dag ordinarie utdelning CI 0.00 SEK
2020-04-16 - Årsstämma
2020-02-14 - Bokslutskommuniké 2019
2019-11-05 - Kvartalsrapport 2019-Q3
2019-08-06 - Kvartalsrapport 2019-Q2
2019-04-23 - Kvartalsrapport 2019-Q1
2019-04-12 - X-dag ordinarie utdelning CI 0.00 SEK
2019-04-11 - Årsstämma
2019-02-12 - Bokslutskommuniké 2018
2018-11-06 - Kvartalsrapport 2018-Q3
2018-08-03 - Kvartalsrapport 2018-Q2
2018-05-04 - Kvartalsrapport 2018-Q1
2018-04-13 - X-dag ordinarie utdelning CI 0.00 SEK
2018-04-12 - Årsstämma
2018-02-02 - Bokslutskommuniké 2017
2017-10-27 - Kvartalsrapport 2017-Q3
2017-07-21 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning CI 0.00 SEK
2017-05-11 - Årsstämma
2017-04-28 - Kvartalsrapport 2017-Q1
2017-01-27 - Bokslutskommuniké 2016
2016-10-21 - Kvartalsrapport 2016-Q3
2016-07-15 - Kvartalsrapport 2016-Q2
2016-05-13 - X-dag ordinarie utdelning CI 0.00 SEK
2016-05-12 - Årsstämma
2016-04-22 - Kvartalsrapport 2016-Q1
2016-01-29 - Bokslutskommuniké 2015
2015-10-23 - Kvartalsrapport 2015-Q3
2015-07-17 - Kvartalsrapport 2015-Q2
2015-05-08 - X-dag ordinarie utdelning CI 0.00 SEK
2015-05-07 - Årsstämma
2015-04-24 - Kvartalsrapport 2015-Q1
2015-01-30 - Bokslutskommuniké 2014
2014-10-24 - Kvartalsrapport 2014-Q3
2014-07-18 - Kvartalsrapport 2014-Q2
2014-05-16 - X-dag ordinarie utdelning CI 0.00 SEK
2014-05-15 - Årsstämma
2014-04-24 - Kvartalsrapport 2014-Q1
2014-01-31 - Bokslutskommuniké 2013
2013-10-18 - Extra Bolagsstämma 2013
2013-10-11 - Kvartalsrapport 2013-Q3
2013-07-19 - Kvartalsrapport 2013-Q2
2013-04-25 - X-dag ordinarie utdelning CI 0.00 SEK
2013-04-24 - Årsstämma
2013-04-19 - Kvartalsrapport 2013-Q1
2013-01-22 - Bokslutskommuniké 2012

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorEnergi & Miljö
IndustriEnergikällor
Cell Impact är ett teknikbolag inriktade mot den industriella sektorn. Bolaget producerar och levererar flödesplattor och produktionsteknologi till tillverkare av bränsleceller. Bolaget har utvecklat och patenterat en metod för höghastighetsformning (adiabatic high-velocity forming) som gör det möjligt att tillverka flödesplattor med hög energidensitet. Störst marknad återfinns inom transportsektorn, med fokus på lagerfordon, bussar och lättare lastbilar samt personbilar.
2024-10-01 16:45:00

Cell Impact AB (publ) (Nasdaq First North Growth Market: CI) ("Cell Impact" or the "Company") today announces the outcome of exercise of warrants of series 2023/2024 TO2, which were issued in connection with the Company's rights issue of units in December 2023. In total, 104,821,096 warrants of series 2023/2024 TO2 were exercised, corresponding to approximately 81 percent of the total number of outstanding warrants of series 2023/2024 TO2, for subscription of 104,821,096 shares at a subscription price corresponding to SEK 0.17 per share. Cell Impact will receive approximately SEK 18 million before issuing costs through the exercise of the warrants of series 2023/2024 TO2.

Background
The subscription period for exercise of warrants of series 2023/2024 TO2 took place during the period from and including 16 September 2024, up to and including 30 September 2024. The subscription price per share for exercising the warrants of series 2023/2024 TO2 was set to SEK 0.17, corresponding to 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the measurement period 2 September 2024 up to and including 13 September 2024.

In total, 104,821,096 warrants of series 2023/2024 TO2 were exercised for subscription of 104,821,096 shares, corresponding to approximately 81 percent of the total number of warrants of series 2023/2024 TO2.

Shares that have been subscribed and paid for will be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into shares in Cell Impact.

Number of shares, share capital and dilution
Through the exercise of the warrants of series 2023/2024 TO2, the number of shares in Cell Impact increased by 104,821,096 shares, from 591,450,032 shares to a total of 696,271,128 shares. The share capital will increase by approximately SEK 12,133,686.80, from approximately SEK 68,463,980.24 to approximately SEK 80,597,667.04.

For existing shareholders who did not exercise any warrants of series 2023/2024 TO2, the dilution amounts to approximately 15 percent of the number of shares and votes in the Company.

Advisers
Carnegie Investment Bank AB (publ) acts as Sole Global Coordinator and Joint Bookrunner and Pareto Securities AB as Joint Bookrunner. Advokatfirman Vinge is a legal adviser to the Company and Baker McKenzie represents Sole Global Coordinator and Joint Bookrunners in connection with the rights issue.

This information is inside information that Cell Impact AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on 1 October 2024 at 16:45 CEST.